Ajinomoto Bio-Pharma Services
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ajinomoto Bio-Pharma Services
With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.
MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- Granules OmniChem Private Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.